Issie Kirby
Stock Analyst at Redburn Atlantic
(1.27)
# 3,427
Out of 4,854 analysts
7
Total ratings
25%
Success rate
0.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Issie Kirby
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DXCM DexCom | Upgrades: Buy | $85 → $115 | $86.67 | +32.69% | 2 | Feb 3, 2025 | |
| ALC Alcon | Upgrades: Neutral | n/a | $87.79 | - | 1 | Oct 10, 2024 | |
| TNDM Tandem Diabetes Care | Initiates: Buy | $60 | $20.78 | +188.74% | 1 | May 30, 2024 | |
| PODD Insulet | Initiates: Buy | $235 | $311.77 | -24.62% | 1 | May 30, 2024 | |
| COO The Cooper Companies | Upgrades: Buy | $125 | $72.33 | +72.82% | 2 | Mar 19, 2024 |
DexCom
Feb 3, 2025
Upgrades: Buy
Price Target: $85 → $115
Current: $86.67
Upside: +32.69%
Alcon
Oct 10, 2024
Upgrades: Neutral
Price Target: n/a
Current: $87.79
Upside: -
Tandem Diabetes Care
May 30, 2024
Initiates: Buy
Price Target: $60
Current: $20.78
Upside: +188.74%
Insulet
May 30, 2024
Initiates: Buy
Price Target: $235
Current: $311.77
Upside: -24.62%
The Cooper Companies
Mar 19, 2024
Upgrades: Buy
Price Target: $125
Current: $72.33
Upside: +72.82%